Syndax Pharmaceuticals Inc. ((SNDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The MAXPIRe study, officially titled A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF), aims to assess the effectiveness and safety of axatilimab for treating IPF. This study is significant as it explores a potential new treatment for a challenging lung condition.
Intervention/Treatment: The study tests axatilimab, an experimental drug administered via intravenous infusion, against a placebo. Axatilimab is designed to treat IPF by potentially reducing inflammation and fibrosis in the lungs.
Study Design: This Phase 2 clinical trial is interventional, with participants randomly assigned to either the axatilimab or placebo group. The study uses a parallel model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are unaware of the group assignments. The primary purpose is treatment evaluation.
Study Timeline: The study began on November 9, 2023, with primary completion expected by August 21, 2025, which is also the date of the last update. These dates are crucial for tracking progress and anticipating results.
Market Implications: Syndax Pharmaceuticals’ stock performance could be positively influenced by this study if axatilimab proves effective, potentially boosting investor confidence. The competitive landscape in IPF treatments is evolving, and successful outcomes could position Syndax favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.